Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436218 | 0.82 | KDM4E (0.67) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL20564592 | 0.80 | HSD17B10 (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL15935 | 0.80 | HSD17B10 (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL3873222 | 0.80 | HSD17B10 (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL9193218 | 0.80 | HSD17B10 (0.95) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL24368139 | 0.78 | HSD17B10 (0.91) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL9251512 | 0.78 | KDM4E (0.61) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL936468 | 0.78 | HSD17B10 (0.91) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL7351182 | 0.78 | KDM4E (0.61) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL6858111 | 0.78 | HSD17B10 (1.00) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105237549-A | Synthetic method for sirolimus 40-ether derivative | ZHEJIANG MED XINCHANG PHARM | 2016-01-13 | — | — | CN | claimed |
| EP-0765160-B1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | UNIV RAMOT (IL) | 2003-04-16 | — | — | EP | claimed |
| US-6096740-A | BLOCK N-METHYL-ASPARTATE | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2000-08-01 | — | — | US | claimed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| EP-0765160-A4 | — | — | 1997-04-09 | — | — | EP | claimed |
| EP-0765160-A1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | RAMOT UNIVERSITY, AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 1997-04-02 | — | — | EP | claimed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | claimed |
| WO-1995020958-A1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1995-08-10 | — | — | WO | claimed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | claimed |
| US-10100095-B2 | Resistant mutant 90 kDa heat shock protein | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20160311871-A1 | RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3064582-A1 | RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-2662357-B1 | BICYCLIC COMPOUNDS OR SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-103142632-B | The Macrolide being used for the treatment of disease mediated by suppressing PDE | BASLIER PHARMACEUTICAL AG (CH) | 2016-01-20 | — | — | CN | disclosed |
| US-5302730-A | Acylation with acetic acid at positions one and seven; eliminating acyl group at position seven by solvolysis | NIPPON KAYAKU KK (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0297496-B1 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1994-01-19 | — | — | EP | disclosed |
| EP-0226896-B1 | LANKACIDIN DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5245052-A | PROCESS FOR PRODUCING 6-ACYL-7-DEACETYLFORSKOLIN DERIVATIVES | NIPPON KAYAKU CO. LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0469428-A1 | Novel process for producing 6-acyl-7-deacetylforskolin derivatives | HOECHST JAPAN LIMITED (JP) | 1992-02-05 | — | — | EP | disclosed |
| EP-0297496-A2 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311871-A1 | RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN | HSP90AB1, HSP90AA1, HSP90AB2P | KDM4E 2950/4885HSD17B10 2377/4885ALOX15 4805/4885 |
| US-10100095-B2 | Resistant mutant 90 kDa heat shock protein | HSP90AB1, HSP90AA1, HSP90AB2P | KDM4E 2950/4885HSD17B10 2377/4885ALOX15 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.